Patents by Inventor Brian W. Metcalf

Brian W. Metcalf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20230322704
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: November 4, 2022
    Publication date: October 12, 2023
    Inventors: Brian W. Metcalf, Zhe Li, Qing Xu, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20220402940
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: August 12, 2022
    Publication date: December 22, 2022
    Inventors: Zhe Li, Qing Xu, Brian W. Metcalf, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • Compounds and uses thereof for the modulation of hemoglobin
    Patent number: 11530191
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: December 20, 2022
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Brian W. Metcalf, Zhe Li, Qing Xu, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • Pyrimidinones as PI3K inhibitors
    Patent number: 11401280
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: August 2, 2022
    Assignees: Incyte Holdings Corporation, Incyte Corportion
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20220119407
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: January 3, 2022
    Publication date: April 21, 2022
    Inventors: Zhe Li, Qing Xu, Brian W. Metcalf, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • Compounds and uses thereof for the modulation of hemoglobin
    Patent number: 11236109
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: February 1, 2022
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Qing Xu, Brian W. Metcalf, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20210261520
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: September 21, 2020
    Publication date: August 26, 2021
    Inventors: Brian W. Metcalf, Zhe Li, Qing Xu, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • Processes for Preparing Jak Inhibitors and Related Intermediate Compounds
    Publication number: 20210253584
    Abstract: The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Application
    Filed: February 16, 2021
    Publication date: August 19, 2021
    Inventors: Jiacheng Zhou, Pingli Liu, Qiyan Lin, Brian W. Metcalf, David Meloni, Yongchun Pan, Michael Xia, Mei Li, Tai-Yuen Yue, James D. Rodgers, Haisheng Wang
  • PYRIMIDINONES AS PI3K INHIBITORS
    Publication number: 20210253601
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: September 30, 2020
    Publication date: August 19, 2021
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • Modulators of hemoglobin
    Patent number: 11014884
    Abstract: The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: May 25, 2021
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Brian W. Metcalf, Zhe Li, Qing Xu, Kobina N. Dufu, James Partridge, Hing Sham, Ming Yu
  • Pyrimidinones as PI3K inhibitors
    Patent number: 10829502
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: November 10, 2020
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • Compounds and uses thereof for the modulation of hemoglobin
    Patent number: 10829470
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: November 10, 2020
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Brian W. Metcalf, Zhe Li, Qing Xu, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • MODULATORS OF HEMOGLOBIN
    Publication number: 20200140384
    Abstract: The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
    Type: Application
    Filed: September 30, 2019
    Publication date: May 7, 2020
    Inventors: Brian W. Metcalf, Zhe Li, Qing Xu, Kobina N. Dufu, James Partridge, Hing Sham, Ming Yu
  • PYRIMIDINONES AS PI3K INHIBITORS
    Publication number: 20200123176
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: August 20, 2019
    Publication date: April 23, 2020
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20200048280
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 18, 2019
    Publication date: February 13, 2020
    Inventors: Zhe Li, Qing Xu, Brian W. Metcalf, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • Compounds and uses thereof for the modulation of hemoglobin
    Patent number: 10435393
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: October 8, 2019
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Qing Xu, Zhe Li, Brian W. Metcalf
  • Pyrimidinones as PI3K inhibitors
    Patent number: 10428087
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: October 1, 2019
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • SALTS OF (S)-7-(1-(9H-PURIN-6-YLAMINO)ETHYL)-6-(3-FLUOROPHENYL)-3-METHYL-5H-THIAZOLO[3,2-A]PYRIMIDIN-5-ONE
    Publication number: 20190202840
    Abstract: The present invention relates to salt forms of the phosphoinositide 3-kinase (PI3K) inhibitor (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one, pharmaceutical compositions comprising the same, and methods of using the salts and compositions for the treatment of PI3K-associated diseases such as cancer.
    Type: Application
    Filed: March 7, 2019
    Publication date: July 4, 2019
    Inventors: Yun-Long Li, Brian W. Metcalf, Hui-Yin Li
  • Compounds and uses thereof for the modulation of hemoglobin
    Patent number: 10266551
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: April 23, 2019
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Qing Xu, Brian W. Metcalf, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20190112287
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 30, 2018
    Publication date: April 18, 2019
    Inventors: Brian W. Metcalf, Zhe Li, Qing Xu, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee